BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36158580)

  • 1. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer.
    Cui Y; Feng H; Liu J; Wu J; Zhu R; Huang R; Yan J
    Front Mol Biosci; 2022; 9():1009168. PubMed ID: 36158580
    [No Abstract]   [Full Text] [Related]  

  • 2. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.
    Su Z; Wang C; Pan R; Li H; Chen J; Tan J; Tian X; Lin T; Shen J
    Front Immunol; 2022; 13():1028263. PubMed ID: 36275679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
    Qiu H; Hu X; He C; Yu B; Li Y; Li J
    Front Genet; 2020; 11():12. PubMed ID: 32117435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Song J; Zhu M; Zhao S; Ma Y; Yang T
    Front Mol Biosci; 2021; 8():688298. PubMed ID: 34368227
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
    Zhu S; Zhao Q; Fan Y; Tang C
    BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance and immune landscape of a fatty acid metabolism-related gene signature in colon adenocarcinoma.
    Liu X; Fang X; Lu L; Liu G
    Front Genet; 2022; 13():996625. PubMed ID: 36568396
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Zhang LH; Li LQ; Zhan YH; Zhu ZW; Zhang XP
    Front Mol Biosci; 2021; 8():607090. PubMed ID: 33937319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
    Pan W; Liu X; Liu S
    Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

  • 16. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
    Li H; Chen S; Mi H
    Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
    Sun S; Wang Y; Wang J; Bi J
    J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.
    Yang L; Li C; Qin Y; Zhang G; Zhao B; Wang Z; Huang Y; Yang Y
    Front Oncol; 2021; 11():686044. PubMed ID: 34422642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
    Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
    Front Oncol; 2022; 12():938679. PubMed ID: 35982954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.